Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients
Publisher: Spandidos Publications
ISSN: 2049-9469
Source: Molecular and Clinical Oncology, Vol.2, Iss.5, 2014-01, pp. : 714-718
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.